P748: SINGLE CELL GENOTYPING OF MATCHED BONE MARROW AND PERIPHERAL BLOOD CELLS IN TREATMENT NAIVE AND AZA-TREATED MDS AND CMML

P748: SINGLE CELL GENOTYPING OF MATCHED BONE MARROW AND PERIPHERAL BLOOD CELLS IN TREATMENT NAIVE AND AZA-TREATED MDS AND CMML

Bibliographic Details
Main Authors:	A. Schnegg-Kaufmann, J. Thoms, G. S. Bhuyan, H. Henry, L. Vaughan, K. Rutherford, P. Kakadia, E. Johansson, T. Failes, A. Greg, J. Koval, R. Lindeman, P. Warburton, A. Rodriguez-Meira, A. Mead, A. Unnikrishnan, S. Bohlander, E. Pappaemmanuil, O. Faridani, C. Jolly, F. Zanini, J. Pimanda
Format:	Article
Language:	English
Published:	Wiley 2022-06-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/01.HS9.0000845876.01682.15

Similar Items

Risk-Adapted, Individualized Treatment Strategies of Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML)
by: Jan Philipp Bewersdorf, et al.
Published: (2021-03-01)

P703: THE AIPSS-MDS MACHINE LEARNING MODEL PREDICTS OVERALL SURVIVAL AND LEUKEMIC TRANSFORMATION IN CMML: AN ANALYSIS OF THE SPANISH REGISTRY OF MDS
by: Adrian Mosquera-Orgueira, et al.
Published: (2023-08-01)

Mouse Models of CMML
by: Ekaterina Belotserkovskaya, et al.
Published: (2021-10-01)

Prognostic impact of the bone marrow tumor microenvironment, HLA-I and HLA-Ib expression in MDS and CMML progression to sAML
by: Marcus Bauer, et al.
Published: (2024-12-01)

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
by: Nicholas J. Short, et al.
Published: (2023-07-01)

THIRD GENERATION AUTOLOGOUS MYELOID-DERIVED DENDRITIC CELLS DEVELOPED FROM PATIENTS WITH CMML AND MDS DEMONSTRATE PHENOTYPIC PROPERTIES OF MATURE FUNCTIONAL DENDRITIC CELLS
by: Anderson, K, et al.
Published: (2014)

THREE CASES OF TP53 BIALLELIC-MUTATED AML/MDS BRIDGED TO ALLO-HSCT BY AZA/VEN THERAPY
by: T. Ueda, et al.
Published: (2024-01-01)

P755: HYPERFERRITINEMIA IS A PREDICTIVE BIOMARKER OF POOR CLINICAL OUTCOMES IN CMML
by: L. E. Aguirre, et al.
Published: (2022-06-01)

Transformation of CMML to AML presenting with acute kidney injury
by: Rebecca DeBoer, et al.
Published: (2020-07-01)

P784: A PHASE I/II STUDY OF VENETOCLAX IN COMBINATION WITH ASTX727 (DECITABINE/CEDAZURIDINE) IN TREATMENT‐NAÏVE HIGH‐RISK MYELODYSPLASTIC SYNDROME (MDS) OR CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML)
by: S. Venugopal, et al.
Published: (2022-06-01)

Case Report: CMML in Young Age which Transformed to AML
by: Wilujeng Anggraini, et al.
Published: (2023-11-01)

L3N F748 (263) [fotograf udara]
by: Malaysia. Direktorat Pemetaan Negara

L4S F748 (231-245) [fotograf udara]
by: Malaysia. Direktorat Pemetaan Negara

Addition of Organotin Anions to ÃŽÂ±,ÃŽÂ²-Unsaturated Nitriles
by: V. Lassalle, et al.
Published: (2000-03-01)

GFI1(36N) as a therapeutic and prognostic marker for myelodysplastic syndrome (MDS)
by: Botezatu, L, et al.
Published: (2016)

L3N F748 (260-262) [fotograf udara]
by: Malaysia. Direktorat Pemetaan Negara

L3N F748 (260-262) [fotograf udara]
by: Malaysia. Direktorat Pemetaan Negara

L3N F748 (250-259) [fotograf udara]
by: Malaysia. Direktorat Pemetaan Negara

748 cases of suicide assisted by a Swiss right-to-die organisation
by: E Ulrich, et al.
Published: (2003-05-01)

MDS plus data acquisition system
by: Stillerman, J.A., et al.
Published: (2015)

P562: LEMZOPARLIMAB (LEMZO) WITH VENETOCLAX (VEN) AND/OR AZACITIDINE (AZA) IN PATIENTS (PTS) WITH ACUTE MYELOID LEUKEMIA (AML) OR MYELODYSPLASTIC SYNDROMES (MDS): A PHASE 1B DOSE ESCALATION STUDY
by: J.-Z. Hou, et al.
Published: (2022-06-01)

Treatment Outcomes and Prognostic Factors in 66 Patients with Chronic Myelomonocytic Leukemia (CMML) in a Single Center
by: Wang C, et al.
Published: (2022-10-01)

PLATELET DYSFUNCTION IN A PATIENT WITH CHRONIC MYELOMONOCYTIC LEUKEMIA (CMML) AND RECURRENT SUBDURAL HEMATOMA.
by: JPB Júnior, et al.
Published: (2023-10-01)

Relation between systemic hypertension and sleep hypoxaemia or snoring: analysis in 748 men drawn from general practice.
by: Stradling, JR, et al.
Published: (1990)

Microwave Accelerated Aza-Claisen Rearrangement
by: Eva GajdoÃ…Â¡ÃƒÂkovÃƒÂ¡, et al.
Published: (2008-11-01)

Azas-azas negara dan pemerintah didalam Islam /
by: Muhammad Asad, 1900-, et al.
Published: (1964)

AZAS-AZAS PEMBELAJARAN KONTEKSTUAL DALAM PERSPEKTIF ISLAM
by: Wirdati Wirdati, et al.
Published: (2018-12-01)

Germ-Line TP53 Mutation in an Adolescent With CMML/Atypical CML and Familiar Cancer Predisposition
by: Silvia Nucera, et al.
Published: (2020-10-01)

Generalized GM-MDS: Polynomial Codes Are Higher Order MDS
by: Brakensiek, Joshua, et al.
Published: (2024)

The role of innate immunity in MDS pathogenesis
by: David A. Sallman, et al.
Published: (2019-06-01)

Doubly diastereoselective [3,3]-sigmatropic aza-Claisen rearrangements.
by: Davies, S, et al.
Published: (2009)

Downregulation of Ribosomal Proteins Is Seen in Non 5q-MDS
by: Sohal, P, et al.
Published: (2008)

P743: THE PIVOTAL ROLE OF GLUTAMINOLYSIS IN MYELODYSPLASTIC SYNDROME (MDS): A NOVEL STRATEGY FOR THE TARGETED THERAPY OF MDS
by: S. Okabe, et al.
Published: (2022-06-01)

Fotoudara L3N F748 No.260-262, Skala 1:25000 (Diapositives_)

P748: IPSS-M PERFORMANCE IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AT THE TIME OF HYPOMETHYLATING AGENT FAILURE
by: Samuel Urrutia, et al.
Published: (2023-08-01)

Double diastereoselective [3,3]-sigmatropic aza-Claisen rearrangements.
by: Davies, S, et al.
Published: (2003)

Classification, risk stratification and response assessment in myelodysplastic syndromes/neoplasms (MDS): a state-of-the-art report on behalf of the International Consortium for MDS (icMDS)
by: Stahl, M, et al.
Published: (2023)

Aminophenyl-Aza-BODIPY
by: Dmitry Merkushev, et al.
Published: (2022-12-01)

The weights in MDS codes
by: Ezerman, Martianus Frederic, et al.
Published: (2019)

Survey from 61,748 schools in four States of India on sale of tobacco products near schools
by: Ashima Sarin, et al.
Published: (2024-01-01)